Wolverine Trading’s Travere Therapeutics TVTX Stock Holding History

Wolverine Trading’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$255K	Sell	10,600 -2,700	-20%	-$50.8K	﹤0.01%	4624
2025 Q2	$196K	Buy	+13,300	New	+$220K	﹤0.01%	3928
2025 Q1	–	Sell	-14,700	Closed	-$255K	–	5871
2024 Q4	$255K	Buy	+14,700	New	+$260K	﹤0.01%	4219
2023 Q4	–	Sell	-14,900	Closed	-$133K	–	5237
2023 Q3	$133K	Buy	+14,900	New	+$210K	﹤0.01%	3902
2023 Q2	–	Sell	-11,500	Closed	-$254K	–	4958
2023 Q1	$254K	Buy	+11,500	New	+$244K	﹤0.01%	3186
2019 Q1	–	Sell	-9,400	Closed	-$209K	–	5329
2018 Q4	$209K	Sell	9,400 -18,900	-67%	-$470K	﹤0.01%	3647
2018 Q3	$813K	Buy	+28,300	New	+$809K	﹤0.01%	2565
2017 Q1	–	Sell	-25,500	Closed	-$483K	–	5013
2016 Q4	$483K	Sell	25,500 -27,200	-52%	-$556K	﹤0.01%	2668
2016 Q3	$1.15M	Buy	52,700 +22,300	+73%	+$424K	0.01%	1728
2016 Q2	$546K	Buy	+30,400	New	+$492K	﹤0.01%	2144

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wolverine Trading's TVTX Position: Q1 2019 in Review

Wolverine Trading sold out of Travere Therapeutics (TVTX) in Q1 2019, closing a stake of 10,632 shares — an estimated $235K sold.

Wolverine Trading first reported a position in TVTX in Q2 2016 and held it in 2 quarters. The position peaked at $394K in Q2 2016. 131 funds tracked by Wall St. Rank hold TVTX as of Q1 2019.

Wolverine Trading reported no remaining Travere Therapeutics position as of Q1 2019 after selling out during the quarter.
Wolverine Trading sold 10,632 Travere Therapeutics shares in Q1 2019, an estimated $235K.
Wolverine Trading first reported a position in Travere Therapeutics in Q2 2016 and held it in 2 quarters.
Wolverine Trading's Travere Therapeutics position peaked at $394K in Q2 2016.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2019.

Based on Wolverine Trading's 13F filing for Q1 2019, filed 15 May 2019.